Effector CD8⁺ T cells are enriched in teclistamab responders. T-cell gating for CD4 and CD8 for (A) teclistamab nonresponders and (B) responders. (C) CD8⁺:CD4⁺ T-cell ratios in teclistamab nonresponders vs responders. (D) TEM and (E) TEMRA cell abundance in teclistamab responders vs nonresponders. (F) Feature plots highlighting the differential expression of TIGIT, PD1, CTLA4, LAG3, and TIM3 by TEM and TEMRA CD8⁺ T-cell subpopulations.